A Phase III, Open-label, Randomised, Multi-centre, International Study of MEDI4736, Given as Monotherapy or in Combination with Tremelimumab, Determined by PD-L1 Expression, Versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB IV) who Have Received at Least Two Prior Systemic Treatment Regimens Including One Platinum based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements (ARCTIC)
ID Number 15-0495Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
The clinical research study is being carried out to see if a new cancer treatment, MEDI4736 or MEDI4736 in combination with tremelimumab, is more effective than standard of care in patients with advanced non-small cell lung cancer who have had at least 2 different types of treatment for their cancer before this study. Around 1560 patients like you will be asked to take part in this pre-screening step and from this group, 900 patients will be invited to take part in the main study, which will involve about 250 hospitals around the world.
Recruiting Patients: No